Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 614 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ulcerative Colitis (Disorder) Clear all
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

NCT02895100
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PTG-100, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Los Angeles, California • Colorado Springs, Colorado • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fecal Microbiota Transplantation (FMT) for Treatment of Ulcerative Colitis in Children

NCT01947101
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal Microbiota Transplant
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 20 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 24, 2026, 9:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 24, 2026, 9:18 AM EDT
Active, not recruiting Phase 3 Interventional

ABTECT - Maintenance

NCT05535946
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
16 Years and older
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
72
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Sun City, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

NCT03675477
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 24, 2026, 9:18 AM EDT
Active, not recruiting Phase 2 Interventional

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
emvistegrast, Placebo-to-match emvistegrast
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
57
States / cities
Peoria, Arizona • Camarillo, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 24, 2026, 9:18 AM EDT
Not listed No phase listed Observational

Microbial and Human Determinants of the Onset of IBD Flares

NCT05463900
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated, Crohn Disease in Remission
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

NCT02601300
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GED-0301
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Newport Beach, California • San Diego, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 24, 2026, 9:18 AM EDT
Withdrawn No phase listed Observational

Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease

NCT00783575
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 24, 2026, 9:18 AM EDT
Withdrawn Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

NCT05316220
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 24, 2026, 9:18 AM EDT
Recruiting Phase 1 Interventional

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for Crohn's Disease or Ulcerative Colitis

NCT05003947
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
Biological
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

NCT00385736
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
adalimumab, placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 24, 2026, 9:18 AM EDT
Recruiting No phase listed Observational

IBD Pregnancy Registry

NCT06910553
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Non-exposed group, Exposed to IBD pharmacotherapy during pregnancy
Other · Drug
Lead sponsor
CorEvitas
Network
Eligibility
18 Years to 50 Years · Female only
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Not applicable Interventional

Exploring Multiple Self-Help Interventions to Promote Self-Efficacy and Overcome Disability

NCT06646757
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions
APP, CBT, HELP, PEER
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 24, 2026, 9:18 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05672199
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Efavaleukin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Santa Maria, California • Kissimmee, Florida • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 1 Interventional

High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)

NCT05587673
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Methylprednisolone
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 1Phase 2 Interventional

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

NCT03847467
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
2'-Fucosyllactose, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 25 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Hartford, Connecticut • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

NCT04004611
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Orange, California • San Francisco, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

NCT00628433
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, HE3286
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Tucson, Arizona • Anaheim, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 24, 2026, 9:18 AM EDT
Completed No phase listed Observational

Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease

NCT01349504
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 24, 2026, 9:18 AM EDT
Not yet recruiting Phase 4 Interventional

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

NCT07059130
View directory record Official record
Conditions
Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
Interventions
Mirikizumab
Biological
Lead sponsor
Rubix LS
Industry
Eligibility
60 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT02407236
View directory record Official record
Conditions
Colitis, Ulcerative, Inflammatory Bowel Diseases
Interventions
Placebo IV, Placebo SC, Ustekinumab IV, Ustekinumab SC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • La Mirada, California • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 1 Interventional

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis

NCT03006809
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal Microbiota Transplantation (FMT), OpenBiome, pretreatment antibiotics
Biological · Other
Lead sponsor
Najwa Elnachef
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 24, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

NCT01461317
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
La Jolla, California • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 24, 2026, 9:18 AM EDT